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Abstract
Background: Prosthetic valve endocarditis (PVE) has the highest in-hospital mortality among all cases of infective
endocarditis (IE), it is estimated at about 40 %. Orthotopic heart transplantation (OHT) as a measure of last resort,
may be considered in selected cases where repeated surgical procedures and conservative efforts have failed to
eradicate persistent or recurrent IE. Only few clinical data are available regarding this rare indication for OHT, since
active IE has traditionally been considered as a contraindication for OHT.
Case presentation: We report on a 55 year old male patient who underwent prosthetic valve replacement with
a mechanical valved conduit ten years ago and developed now persistent PVE with severe complications due to
methicillin-resistant Staphylococcus epidermidis (MRSE). Repeated surgical procedures and conservative efforts have
failed to eradicate the pathogen. Regarding the lack of curative options, salvage OHT was discussed as a measure
of last resort. 28 months after the first diagnosis of PVE, the patient was successfully transplanted and is now doing
well under close follow-up (6 months post-OHT).
Conclusions: PVE remains a challenging condition regarding diagnosis and treatment. The presented case underscores
the urgent need for an integrated and multidisciplinary approach to patients with suspected and definitive IE - especially
in PVE. OHT might be a feasible measure of last resort in selected patients with IE. Our case report adds published
clinical experience to this rarely performed procedure and consolidates previous findings.
Keywords: Methicillin-resistant Staphylococcus epidermidis (MRSE), Endocarditis, Rifampicin resistance, Prosthetic heart
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Background
Infective endocarditis (IE) is a severe condition with a
high morbidity and mortality. Epidemiological studies
report an annual incidence between 3 and 7 cases per
100.000 person years [1, 2]. In-hospital mortality ranges
from 15 to 22 %, and overall 5-year mortality is approxi-
mately 40 % [3–5]. The male to female ratio is more
than 2:1 [3]. Over the last years, Staphylococcus aureus
has become the most frequently isolated pathogen in the
context of IE [6–8]. Furthermore, there is an increasing
number of prosthetic valve endocarditis patients and
cardiac device related infective endocarditis cases in the
last decades. National and international guidelines have
been published regarding evidence-based diagnosis and
treatment recommendations for native valve endocardi-
tis (NVE), prosthetic valve endocarditis (PVE) and for
cardiac device related infective endocarditis (CDRIE) [1,
9, 10]. The treatment of IE should nowadays be subject
to an integrated multidisciplinary team approach, includ-
ing cardiologists, infectious disease physicians, cardiac
surgeons and microbiologists. In different clinical cohort
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studies [7, 11], up to 50 % of all IE cases required cardiac
surgery during the active phase of the disease due to
progressive valve regurgitations, perivalvular infection,
vegetation size, recurrent embolisation and heart failure.
The 2015 European Society of Cardiology (ESC) guideline
mentioned cardiac transplantation as a measure of last
resort, which “may be considered in extreme cases where
repeated operative procedures have failed to eradicate
persistent or recurrent PVE” [9]. However, only little
experience and few clinical data are available regarding
this indication for cardiac transplantation, since active IE
has traditionally been regarded as a contraindication for
orthotopic heart transplantation (OHT). Structured litera-
ture search using the search terms “endocarditis”and
“heart transplantation”or “salvage treatment”retrieved only
18 patient cases, including a case series from France
reporting 6 patients (and 10 previously published cases),
who underwent OHT as salvage treatment for IE [12] (see
Additional file 1: Table S1.). In the “Eurotransplant Zone”,
there were 10 patients transplanted between 1995 and
2015 for the diagnosis IE. Median time to transplant was
62 days (range 1 – 180 days) and the median age of the
transplant recipients was 48 years (range 33 – 62 years),
8/10 recipients were male and 8/10 were transplanted in
an urgent/prioritized setting [personal communication].
OHT is a measure of last resort in IE. However, in the era
of extreme donor organ shortage, further studies and pub-
lished clinical experience are needed to evaluate very
carefully, which endocarditis patients might benefit
from OHT.
Case presentation
We report on a 55 year old male patient with a history of
severe aortic valve stenosis, ectasia of the aorta ascendens
(48 mm) and reduced left ventricular function. He under-
went prosthetic valve replacement with a mechanical
valved conduit (St. Jude Medical Conduit CAVG 29 mm)
in 2003. Anticoagulation was started with phenprocou-
mon. Implantation of a cardiac pacemaker (Medtronic
Kappa KDR 503) due to atrioventricular block III° was
necessary five days after initial heart surgery.
The patient presented to the emergency department in
03/2013 with a new sleep-onset weakness of the left arm
and difficulties to speak. Emergency cranial computed-
tomography (CCT) revealed ischemic brain lesions in the
territory of the right middle cerebral artery. Neither atrial
fibrillation nor valvular lesions or carotid artery stenoses
were detected, when the patient was evaluated for causa-
tive mechanisms. Rehabilitation was finally completed with
minimal residual neurological symptoms. Five months
later, the patient was readmitted with fatigue, febrile
temperatures, headache, nausea and progressive left-sided
weakness and dysarthria. CCT scans after readmission
showed signs of the preceding ischemic stroke in the
territory of the right middle cerebral artery and new signs
of progressive embolisation in the territory of the left mid-
dle cerebral artery with haemorrhage. C-reactive protein
(CRP) was now 59 mg/l (ref. <5 mg/l) and the erythrocyte
sedimentation rate (ESR) was 45 mm/h (ref. 0–30 mm/h).
Sequentially obtained blood culture samples (5 of 5 sets)
were positive for Staphylococcus epidermidis resistant to
oxacillin (MRSE) (see Table 1). In line with additional
minor DUKE criteria, predisposition, febrile temperatures
and septic emboli, the definitive diagnosis of infective
prosthetic valve endocarditis (PVE) was made. Antiinfec-
tive treatment with vancomycin plus rifampicin was started
and the patient was transferred to a tertiary university
medical center providing immediate facilities for cardiosur-
gical and neurosurgical interventions. The initial bedside
transthoracic echocardiography on admission revealed no
signs of valvular masses suggestive for vegetations, a
moderate mitral regurgitation was noted. Evaluation via
transesophageal echocardiography 48 h later showed a
filiforme (7x4mm) mass at the prosthetic aortic valve and a
perivalvular dehiscence of the mechanical valved conduit.
Table 1 Evolving Staphylococcus epidermidis resistance patterns
during the course of disease
07/2013 05/2014 04/2015
[Bloodculture
isolates]
[Bloodculture
isolates]
[Bloodculture
isolates]
Daptomycin S S S
Vancomycin S S S
Penicillin G R R R
Flucloxacillin/Oxa R R R
Erythromycin R S R
Clarithromycin S S R
Tetracycline R S S
Ampicillin + Sulb R R R
Amoxicillin + Clav R R R
Imipenem R R R
Cefuroxim R R R
Gentamicin S S S
Moxifloxacin R I R
Levofloxacin R R R
Ciprofloxacin R R R
Cotrimoxazol S R R
Tigecyclin S S S
Fosfomycin S S S
Linezolid S S S
Fusidinsaeure S S S
Rifampicin S R R
Clindamycin S S R
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Fortunately, at this time no surgical intervention was
required.
In 11/2013 the patient developed progressive clinical
signs of heart failure on the basis of severe mitral regurgi-
tation, on transesophageal echocardiography destruction
of the aortic-mitral continuity was noted, which made
a mitral-valve repair intervention impossible. Urgent
prosthetic valve replacement was successfully performed
(St. Jude Medical MJ-501 33 mm). Histopathological sam-
ples showed signs of low grade chronic inflammation.
Tissue samples from the surgical site and swab specimen
from the left ventricular outflow tract (LVOT) were
culturepositive for S. epidermidis (MRSE). In conclusion,
new prosthetic valve material had to be inserted into a
non-sterile situs despite antiinfective pretreatment and
sterile bloodcultures. A curative approach seemed from
that particular time on all but impossible and the patient
was discharged with cotrimoxazol plus rifampicin as a
timely indefinite oral suppressive treatment. Seven months
after mitral valve replacement, in the context of a rising
CRP and progressive fatigue, breakthrough bacteremia
was detected. The MRSE strain isolated from sequential
bloodcultures displayed now resistance against rifampicin
(see Table 1). Bloodstream negativity was achieved after
prolonged treatment with daptomycin plus clindamycin.
From the infectious disease perspective, the presence of
this now isolated “difficult to treat” MRSE strain, together
with lacking surgical options to remove or revise pros-
thetic material resembled a palliative situation, since there
were no substances for effective oral suppression therapy
left. The main concern however, was that in the near
future the progressive destruction of the periprosthetic
tissue between the aortic and mitral valve (Fig. 1) might
result in a fatal valve complication or progressive
embolization to the brain. Regarding the lack of curative
options, salvage OHT was discussed as a measure of
last resort. During the pretransplant workup, prostate
cancer (pT3a, pN0 (0/27), R1, L0, V0, M0; Gleason
Score 3 + 4 = 7a) was diagnosed and the patient was
delisted for OHT due to apparent malignancy. Radical
prostatevesiculectomy was performed with adjuvant
radiotherapy, after an interdisciplinary tumorboard de-
cision. Twelve months later, under oral antiinfective
suppressive therapy with moxifloxacin and clindamycin,
the patient developed febrile temperatures with MRSE
bacteremia – now displaying resistance against clindamy-
cin and all fluoroquinolones. Fortunately, bloodstream
negativity could be induced again with a prolonged course
of daptomycin on an outpatient basis (OPAT). Finally, the
patient was reassessed for OHT under stable conditions,
bloodculture negativity and in line with oncological trans-
plant requirements – 28 months after the first diagnosis
of infective PVE, the patient was successfully transplanted.
In the peri-transplantion period and for four weeks post-
transplantion the patient received daptomycin plus fosfo-
mycin. Bloodcultures remained sterile at any time and in
particular after ending antiinfective treatment. He is now
under close follow-up doing well (6 months post-OHT).
Histopathological examination of the explanted organ
and prosthetic material showed clear evidence of
chronic active IE. Tissue specimen from aortic tissue
were conclusive positive for Staphylococcus epidermidis
on broadspectrum 16 s-PCR. From the isolated tissue
samples the mecA gene encoding for oxacillin resist-
ance was amplified.
Discussion
Prosthetic valve endocarditis remains a challenging condi-
tion regarding diagnosis and treatment, despite improve-
ments in nuclear imaging and molecular techniques. This
distinct entity of IE has the highest in-hospital mortality
among all IE cases, it is estimated at about 40 %. An
observational before/after study from France, including
173 IE patients in the period before the team approach
was implemented and 160 IE patients in the study period
Fig. 1 Transesophageal echocardiography (TEE) findings on
cardiological follow-up evaluation 06/2014 after urgent prosthetic
mitral valve replacement was successfully performed in 11/2013. In the
different views, A and B, the abscess formation (arrows) around the
mechanical valved conduit is shown, which has direct contact to the
left ventricle (LV). LA denotes for the left atrium, RA right atrium and
Ao aorta ascendens
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after a standardized protocol was established, reported
a significant reduction in endocarditis related mortal-
ity and complications [13]. A very similar collabora-
tive approach published in a study from Italy showed
an improvement in NVE-related mortality [14]. Con-
sequently, the “Endocarditis Team” was recommended
as Ib in the 2014 AHA guideline for the management of
patients with valvular disease and strongly supported (Class
IIa recommendation) by the 2015 ESC endocarditis
guideline [9]. Such teams should include specialists from
various clinical disciplines - infectious disease specialists,
cardiologists, cardiac surgeons, microbiologists, neurolo-
gists and neurosurgeons [9]. The presented case underlines
the urgent need for an integrated and multidisciplinary
approach to patients with suspected and definitive IE to
prevent fatal complications and facilitate optimal treatment
in the different clinical settings, ranging from primary to
tertiary care providers. Retrospectively, the choice of anti-
infective substances (for overview see Additional file 2:
Table S2), combination therapy and aspects of dosing
might be a matter of discussion – however, this would go
beyond the scope of this case report. Overall, OHT as
salvage therapy of IE remains a rare transplant indication.
Only scarce clinical experience is available on the basis of
several published case reports and one small case series
[12]. It must be pointed out, that published data might be
biased. Favourable outcomes are more likely to be submit-
ted and published than treatment failure. Data retrieved
from the Eurotransplant register indicate a high waiting list
mortality with 10 patients that were transplanted and 8
patients died waiting for an organ of the total of 18
patients that were actually listed for OHT with the
indication IE in the period between 1995 and 2015
[personal communication].
In the era of organ shortages, further clinical studies
and structured follow-up data are needed to carefully
evaluate patients with IE, who might be eligible for
OHT. Repeated sets of sterile blood cultures, i.e., the
absence or effective suppression of bacteremia, seems to
be one important requirement for OHT in this particu-
lar clinical situation. With respect to OHT in the setting
of bacteremia and PVE, there are no data available.
Driveline infections (DLIs) in the context left ventricular
assist devices (LVADs) and consecutive OHT might
resemble very similar clinical situations [15]. A recently
published small retrospective study, comparing patients
transplanted with active DLI (n = 12) versus no DLI
(n = 26) showed no differences in mortality and length of
hospital stay [16]. However, the safety of OHT in patients
with uncontrolled infections remains unclear.
Conclusion
PVE remains a challenging condition regarding diagnosis
and treatment. The presented case underscores the urgent
need for an integrated and multidisciplinary approach to
patients with suspected and definitive IE - especially in
PVE. OHT might be a feasible measure of last resort in
selected patients with IE. Our case report adds published
clinical experience to this rarely performed procedure and
consolidates previous findings.
Additional files
Additional file 1: Table S1. Prosthetic valve endocarditis – PVE;
Native valve endocarditis – NVE; OHT – orthotopic heart transplantation
(DOCX 15 kb)
Additional file 2: Table S2. Course of antiinfective treatment.
(DOCX 13 kb)
Abbreviations
AHA, American Heart Association; Ao, aorta; CCT, cranial computed
tomography; CDRIE, cardiac device related infective endocarditis; DLI, drive
line infection; ESC, European Society of Cardiology; IDSA, Infectious Disease
Society of America; IE, infective endocarditis; LA, left atrium; LV, left ventricle;
LVAD, left ventricular assist device; LVOT, left ventricular outflow tract; mecA,
mecA gene encodes for methicillin resistance; MRSE, methicillin resistant
staphylococcus epidermidis; NVE, native valve endocarditis; OHT, orthotopic
heart transplantation; OPAT, outpatient antibiotic treatment; PVE, prosthetic
valve endocarditis; RA, right atrium; RV, right ventricle
Acknowledgements
The article processing charge was funded by the German Research
Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding
programme Open Access Publishing.
Funding
None.
Authors’ contributions
JPB drafted and wrote the manuscript, he was substantially involved in the
patient management. AH critically revised the manuscript, was involved in
clinical decision making and administered figures. GS and AD performed all
microbiological and advanced molecular diagnostic studies. FL contributed
histopathological expertise. AR and PE headed the transplant team and provided
figures. WHK prepared epidemiological data regarding OHT and IE/PVE in the
“Eurotransplant Zone”. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
There was no ethics approval needed; the patient provided consent to
participate. The consent form is available on request by the corresponding
author.
Author details
1Department of Internal Medicine, Ortenauklinikum Achern-Oberkirch,
Division of Infectious Diseases, Josef-Wurzler-Straße 7, 77855 Achern,
Germany. 2MVZ Clotten, Labor Dr. Haas, Dr. Raif & Kollegen, Merzhausener
Straße 112a, 79100 Freiburg i.Br, Germany. 3Eurotransplant International
Foundation, P.O. Box 2304, 2301 CH Leiden, The Netherlands. 4Department
of Cardiac Surgery, Heidelberg University Hospital Center, Im Neuenheimer
Feld 324, 69120 Heidelberg, Germany. 5Department of Cardiology,
Heidelberg University Hospital Center, Im Neuenheimer Feld 410, 69120
Heidelberg, Germany. 6Institute of Pathology, Heidelberg University Hospital
Center, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany.
7Department of Infectious Diseases, Medical Microbiology and Hygiene,
Heidelberg University Hospital Center, Im Neuenheimer Feld 324, 69120
Heidelberg, Germany. 8Department of Medicine, Division of Infectious
Disease and Travel Medicine, Freiburg University Medical Center, Hugstetter
Str. 55, 79106 Freiburg i.Br, Germany.
Borde et al. Journal of Cardiothoracic Surgery  (2016) 11:100 Page 4 of 5
Received: 20 March 2016 Accepted: 6 July 2016
References
1. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al.
Infective endocarditis in adults: diagnosis, antimicrobial therapy, and
management of complications: a scientific statement for healthcare
professionals from the American Heart Association. Circulation. 2015;132:
1435–86.
2. Correa de Sa DD, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD,
et al. Epidemiological trends of infective endocarditis: a population-based
study in Olmsted County, Minnesota. Mayo Clin Proc. 2010;85:422–6.
3. Hoen B, Duval X. Infective endocarditis. N Engl J Med. 2013;369:785.
4. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis:
results of a contemporary population-based profile of 1536 patients in
Australia. Eur Heart J. 2010;31:1890–7.
5. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B,
et al. Preeminence of Staphylococcus aureus in infective endocarditis: a
1-year population-based survey. Clin Infect Dis. 2012;54:1230–9.
6. Federspiel JJ, Stearns SC, Peppercorn AF, Chu VH, Fowler VG. Increasing US
rates of endocarditis with Staphylococcus aureus: 1999–2008. Arch Intern
Med. 2012;172:363–5.
7. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, et al. Clinical
presentation, etiology, and outcome of infective endocarditis in the 21st
century: the International Collaboration on Endocarditis-Prospective Cohort
Study. Arch Intern Med. 2009;169:463–73.
8. Le Moing V, Alla F, Doco-Lecompte T, Delahaye F, Piroth L, Chirouze C, et al.
Staphylococcus aureus bloodstream infection and endocarditis–a
Prospective Cohort Study. PLoS One. 2015;10:e0127385.
9. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et
al. 2015 ESC Guidelines for the management of infective endocarditis. Eur
Heart J. 2015;36:ehv319.
10. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, et
al. Update on cardiovascular implantable electronic device infections and
their management: a scientific statement from the American Heart
Association. Circulation. 2010;121:458–77.
11. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, et al. Association
between valvular surgery and mortality among patients with infective
endocarditis complicated by heart failure. JAMA. 2011;306:2239–47.
12. Aymami M, Revest M, Piau C, Chabanne C, Le Gall F, Lelong B, et al. Heart
transplantation as salvage treatment of intractable infective endocarditis.
Clin Microbiol Infect. 2015;21:371. e1–4.
13. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, et al.
Dramatic reduction in infective endocarditis-related mortality with a
management-based approach. Arch Intern Med. 2009;169:1290–8.
14. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, et al. Impact
of a multidisciplinary management strategy on the outcome of patients
with native valve infective endocarditis. Am J Cardiol. 2013;112:1171–6.
15. Leuck A-M. Left ventricular assist device driveline infections: recent
advances and future goals. J Thorac Dis. 2015;7:2151–7.
16. Bhatia N, Voelkel AJ, Hussain Z, Sharma UC, Slaughter MS, Birks EJ, et al.
Safety and feasibility of induction immunosuppression when driveline
infection is an indication for cardiac transplantation. Thorac Cardiovasc Surg.
2015;63:675–83.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Borde et al. Journal of Cardiothoracic Surgery  (2016) 11:100 Page 5 of 5
